Search

Search Constraints

You searched for: Author/Creator Binotto, Gianni

Search Results

1. "Variant‐specific discrepancy when quantitating BCR‐ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay." Is dPCR the key?. (7th July 2019)

2. Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Issue 10 (October 2015)

3. Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real‐life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart. Issue 3 (17th April 2019)

4. BCR:ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the "GRUPPO TRIVENETO LMC". (8th October 2022)

6. Bosutinib in the real‐life treatment of chronic myeloid leukemia patients aged >65 years resistant/intolerant to previous tyrosine‐kinase inhibitors. Issue 3 (13th March 2021)

7. Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second‐generation tyrosine kinase inhibitors in the real‐life practice: Identification of risk factors and the role of prophylaxis. Issue 7 (28th April 2018)

9. Combination of EUTOS score and 3‐month BCR‐ABL transcript level identifies a group of good‐risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. Issue 7 (28th May 2015)

10. COVID‐19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. (11th October 2021)